Current Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines recommend that Hb ≥110–115 g/L be the target for anemia treatment in CKD patients, and it is strongly recommended that Hb >130 g/L be avoided [10]. This evidence concerns the gene GSTM1 and kidney disorder.